IPP Bureau
Moderna wins EU backing for world’s first combined flu-COVID shot
By IPP Bureau - March 02, 2026
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer
By IPP Bureau - March 02, 2026
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
IRLAB Therapeutics doses first patient in pivotal apathy trial
By IPP Bureau - March 02, 2026
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Chennai gets first structured geriatric continuity-of-care programme
By IPP Bureau - March 02, 2026
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
SEOPRO stuns pharma leaders with AI-driven portfolio management at EBMPPPM 2026
By IPP Bureau - March 02, 2026
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
Zenex Animal Health makes strategic European play with VievePharm acquisition
By IPP Bureau - March 02, 2026
VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets
Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply
By IPP Bureau - March 02, 2026
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Blue Jet Healthcare breaks ground on Rs. 2,300 crore pharma plant in Andhra Pradesh
By IPP Bureau - March 02, 2026
The facility is expected to become operational by FY2028-29
Emcure partners with Roche to boost nephrology and transplant care in India
By IPP Bureau - March 02, 2026
Emcure to distribute Roche's kidney transplant and anemia drugs in India
Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
By IPP Bureau - March 02, 2026
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Lupin receives EIR from FDA for its Goa facility
By IPP Bureau - February 28, 2026
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus hits Keytruda biosimilar milestone with successful FYB206 trial, targets USFDA filing
By IPP Bureau - February 28, 2026
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Glenmark Pharmaceuticals USA to launch sodium phosphates injection
By IPP Bureau - February 28, 2026
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
By IPP Bureau - February 28, 2026
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
